An open-label, proof-of-concept, Phase 2 trial evaluating safety and efficacy of Otlertuzumab in combination with bendamustine in patients with relapsed or refractory peripheral T-cell lymphomas (PTCL)

Trial Profile

An open-label, proof-of-concept, Phase 2 trial evaluating safety and efficacy of Otlertuzumab in combination with bendamustine in patients with relapsed or refractory peripheral T-cell lymphomas (PTCL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Bendamustine (Primary) ; Otlertuzumab (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 08 Jan 2018 Status changed from planning to recruiting, according to an Aptevo Therapeutics media release.
    • 30 Nov 2017 New trial record
    • 28 Nov 2017 According to an Aptevo Therapeutics media release, the company is planning to initiate this trial in the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top